Determining the outcome of targeting pathways that confer resistance to EZH2 inhibitors in DLBCL cells. DLBCL cells (SU-DHL-10, WSU-DLCL-2, and KARPAS-422) were treated with GSK126 at the indicated concentrations in combination with 0.1 μM pictilisib (A-C), 0.1 μM trametinib (D-F), or 1 μM linsitinib (G-I) and their sensitivity to GSK126 was determined using an MTT assay 72 hours after treatment. The cell viability relative to DMSO-treated cells is shown. AUC was calculated to allow for the comparison between the 2 curves and the P values were calculated using a Student t test. Data are presented as mean ± SEM. *P < .05; **P < .01; ***P < .001. ns, not significant.